Approach to Bradycardia

Immediately assess whether the bradycardia is causing symptoms—asymptomatic bradycardia requires no treatment regardless of heart rate, while symptomatic bradycardia demands urgent evaluation for reversible causes followed by atropine as first-line therapy. 1

Initial Assessment

Define Symptomatic vs. Asymptomatic Bradycardia

Symptomatic bradycardia is defined as heart rate typically <50 bpm accompanied by altered mental status, ischemic chest discomfort, acute heart failure, hypotension (systolic BP <80–90 mmHg), syncope, or shock. 1
Asymptomatic bradycardia—even with rates as low as 37–40 bpm—requires no treatment, monitoring, or intervention (Class III: Not indicated). 1, 2
The correlation between documented bradycardia and symptoms is the critical determinant for therapy; asymptomatic bradycardia is common in athletes, during sleep, and in young healthy individuals. 1, 2

Immediate Stabilization Steps

Maintain patent airway and assist breathing as necessary; provide supplemental oxygen if hypoxemic or showing increased work of breathing. 1, 3
Establish cardiac monitoring to identify rhythm, monitor blood pressure, and measure oxygen saturation. 1, 3
Establish IV access for medication administration. 1, 3
Obtain a 12-lead ECG to document rhythm, rate, PR interval, QRS duration, and bundle-branch block patterns—but do not delay treatment in unstable patients. 1, 3

Identify and Treat Reversible Causes (Class I Priority)

Before any pharmacologic or device therapy, systematically evaluate and correct reversible etiologies—this is the highest priority. 1

Reversible Cause	Evaluation	Treatment
Medications (β-blockers, non-DHP CCBs, digoxin, amiodarone, sotalol, ivabradine)	Review drug list	Discontinue or reduce dose [1,2]
Hypothyroidism	Serum TSH & free T4	Initiate levothyroxine replacement [1,2]
Electrolyte abnormalities	Serum K⁺, Mg²⁺	Correct hypo-/hyperkalemia and hypomagnesemia [1,3]
Acute myocardial infarction (especially inferior)	Cardiac biomarkers, ECG	Treat ischemia; bradycardia often resolves [1,3]
Drug overdose (β-blocker, CCB)	History of ingestion	Glucagon 3–10 mg IV bolus, then 3–5 mg/h infusion [1]
Obstructive sleep apnea	Clinical suspicion, sleep study	Initiate CPAP therapy [1,3]
Elevated intracranial pressure	Neuroimaging, neuro exam	Neurosurgical consultation [1,3]
Hypothermia	Core temperature	Active rewarming [1]
Infections (Lyme, viral myocarditis)	Clinical context, serology	Appropriate antimicrobial therapy [1]

Special Antidotes for Toxic Overdose (Class I)

Calcium-channel-blocker toxicity: 10% calcium chloride 1–2 g IV q10–20 min or 10% calcium gluconate 3–6 g IV q10–20 min. 1
β-blocker or CCB overdose: Glucagon 3–10 mg IV bolus, then 3–5 mg/h infusion. 1
Inferior MI with high-grade AV block: Aminophylline 250 mg IV bolus. 1

Acute Pharmacologic Management

First-Line: Atropine (Class I/IIa)

Administer atropine 0.5–1 mg IV push immediately for symptomatic bradycardia; repeat every 3–5 minutes up to a maximum total dose of 3 mg (or 2–3 mg in post-MI patients). 1, 3

Doses <0.5 mg must be avoided because they may paradoxically worsen bradycardia via parasympathomimetic effects. 1
Absolute contraindication (Class III: Harm): Do not give atropine to heart-transplant recipients without autonomic re-innervation—it may precipitate high-grade AV block or sinus arrest. 1

When Atropine Is Effective (Nodal-Level Blocks)

Sinus bradycardia, first-degree AV block, and Mobitz I (Wenckebach) second-degree AV block respond well to atropine. 1
Vagally-mediated bradycardia (e.g., inferior MI within first 6 hours) is likely to improve. 1

When Atropine Is Ineffective or Contraindicated (Class III)

Mobitz II second-degree AV block with wide QRS indicates infranodal block; atropine does not improve conduction and may worsen the block. 1
Third-degree AV block with wide QRS is similarly unresponsive to atropine. 1
Anterior MI with new bundle-branch block suggests infranodal pathology; atropine is contraindicated. 1

Second-Line: Chronotropic Infusions (Class IIb)

If bradycardia persists after maximum atropine dose (3 mg total), initiate chronotropic infusions—but only when the patient has low risk for coronary ischemia. 1

Agent	Initial Dose	Titration & Max Dose	Preferred Clinical Scenario
Dopamine	5–10 µg/kg/min IV	Increase by 2–5 µg/kg/min every 2 min; max 20 µg/kg/min	Most bradyarrhythmias; provides combined chronotropic and inotropic support [1]
Epinephrine	2–10 µg/min IV (or 0.1–0.5 µg/kg/min)	Titrate to heart-rate/BP response	Severe hypotension requiring combined chronotropic, inotropic, and vasopressor effects; heart-transplant patients [1]
Isoproterenol	20–60 µg IV bolus or 1–20 µg/min infusion	Titrate to heart-rate response	Ischemic cardiomyopathy when pure β-agonism is desired (no vasoconstriction) [1]

Critical Warnings

Do not exceed dopamine 20 µg/kg/min—higher doses cause excessive vasoconstriction and arrhythmias without additional heart-rate benefit. 1
All chronotropic agents increase myocardial oxygen demand and may exacerbate ischemia in acute coronary syndromes; target heart rate ≈60 bpm. 1
Avoid catecholamines in patients at high risk for coronary ischemia (Class I). 1

Transcutaneous Pacing (Class IIa)

Initiate transcutaneous pacing immediately in unstable patients who do not respond to atropine—do not delay pacing while administering additional atropine doses. 1, 3

Transcutaneous pacing serves as a bridge to transvenous or permanent pacing. 1, 3
Sedation/analgesia may be required because the procedure can be painful in conscious patients. 1
Recent multicenter data show sustained electrical capture during prehospital transcutaneous pacing was uncommon (9.7%), associated with lower pre-TCP heart rate, higher delivered current, and lower body weight. 4

Transvenous Pacing (Class IIa)

Indicated for persistent hemodynamic instability refractory to medical therapy until permanent pacemaker placement or resolution of reversible cause. 1
Complication rate 14–40% including venous thrombosis (18–85% with femoral approach), pulmonary emboli (50–60%), arrhythmias, loss of capture, and perforation. 1
Temporary wires increase the risk of permanent-pacemaker infection. 1
A 2020 multicenter study found that delayed permanent pacemaker implantation (≥3 days) was not associated with increased adverse events compared to early implantation (≤2 days), whereas temporary transvenous pacing was associated with higher adverse events (19.1% vs 3.4%). 5

Indications for Permanent Pacemaker

Class I (Strong Recommendation)

Symptomatic bradycardia persisting after reversible causes have been excluded or adequately treated. 1, 2
High-grade AV block (Mobitz II or third-degree) with symptoms. 1, 2
Symptomatic sinus node dysfunction with documented bradycardia. 1, 2
Bradycardia caused by essential guideline-directed medical therapy when no alternative treatment exists and continued therapy is clinically necessary. 1

Class IIa (Reasonable)

Tachy-brady syndrome with symptoms clearly attributable to bradycardia. 1
Symptomatic chronotropic incompetence with rate-responsive programming. 1

Class III (Not Indicated)

Asymptomatic sinus node dysfunction. 1
Symptoms clearly present without accompanying bradycardia. 1

Diagnostic Monitoring for Intermittent Symptoms

Correlation of documented bradycardia with symptoms is the gold standard before permanent pacing. 1

Symptom Frequency	Monitoring Strategy	Guideline Class
Daily or near-daily	24–72 h Holter monitor	Class I [1]
Weekly	7–30 day event recorder	Class I [1]
Monthly or less frequent	Implantable loop recorder (diagnostic yield ≈43–50% at 2 yr, ≈80% at 4 yr)	Class IIa [1]

Pacing Mode Selection

Atrial-based pacing (AAI or DDD) is preferred over single-chamber ventricular pacing for sinus node dysfunction with intact AV conduction (Class I). 1
Dual-chamber devices should be programmed to minimize ventricular pacing when AV conduction is preserved (Class I). 1
Rate-responsive programming is reasonable for patients with chronotropic incompetence (Class IIa). 1
A 2015 systematic review found dual-chamber pacemakers cost-effective compared to single-chamber atrial pacemakers (ICER £6506), with reduced reoperation risk (OR 0.48) and reduced paroxysmal atrial fibrillation (OR 0.75). 6

Critical Pitfalls to Avoid

Do not treat asymptomatic bradycardia (even HR <40 bpm) based solely on heart-rate numbers—it may be protective (Class III). 1, 2
Do not delay transcutaneous pacing in unstable patients while administering multiple atropine doses (Class III). 1
Do not exceed a total atropine dose of 3 mg (or 2–3 mg in post-MI patients) to avoid tachycardia and anticholinergic toxicity. 1
Do not use atropine for infranodal blocks (Mobitz II or third-degree with wide QRS)—it will not improve conduction and may worsen the block (Class III). 1
Do not implant a permanent pacemaker before fully evaluating and correcting reversible causes (Class III). 1
Do not start dopamine before attempting atropine—atropine is safer and more appropriate as first-line (Class III). 1

Special Populations

Heart-Transplant Recipients

Atropine is absolutely contraindicated (Class III: Harm)—use epinephrine or dopamine instead. 1
Theophylline or aminophylline (adenosine-receptor blockade) may be considered for refractory bradycardia. 1

Acute Coronary Syndrome

Limit total atropine dose to 2–3 mg and target heart rate ≈60 bpm to prevent tachycardia-induced ischemia. 1
Increasing heart rate with any chronotropic agent may worsen ischemia or increase infarct size. 1

Elderly Patients (≥70 years)

Age alone is not a contraindication to pacing if symptomatic and reversible causes are excluded; decisions should incorporate functional status, life expectancy, and quality-of-life priorities. 1, 2

Athletes

Resting heart rates of 40–50 bpm while awake and 30 bpm during sleep are normal physiologic variants and do not require treatment. 1, 2

Prognosis

Asymptomatic sinus bradycardia has a benign prognosis and does not affect survival (Class I). 1, 2
Symptomatic sinus node dysfunction is associated with high risk of cardiovascular events (syncope, atrial fibrillation, heart failure). 1, 2
Chronotropic incompetence is linked to increased risk of cardiovascular death and overall mortality. 1, 2

What is the appropriate approach to treating symptomatic bradycardia?

Help us tailor your experience